Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents
Until recently it was believed that extracellular gadolinium based contrast agents were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some gadolinium based contrast agents may trigger the development of...
Gespeichert in:
| Veröffentlicht in: | Cancer imaging 2007-09, Vol.7 (1), p.130-137 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 137 |
|---|---|
| container_issue | 1 |
| container_start_page | 130 |
| container_title | Cancer imaging |
| container_volume | 7 |
| creator | Thomsen, Henrik S Marckmann, Peter Logager, Vibeke B |
| description | Until recently it was believed that extracellular gadolinium based contrast agents were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some gadolinium based contrast agents may trigger the development of nephrogenic systemic fibrosis, a generalised fibrotic disorder, in renal failure patients. Accordingly, the use of gadodiamide and gadopentate dimeglumine for renal failure patients was banned in Europe in spring 2007. The same two compounds should only be used cautiously in patients with moderate renal dysfunction. The current paper reviews the situation (July 2007) regarding gadolinium based contrast agent and the severe delayed reaction to some of these agents. The fear of nephrogenic systemic fibrosis should not lead to a denial of a well indicated enhanced magnetic resonance imaging examination. |
| doi_str_mv | 10.1102/1470-7330.2007.0019 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2072086</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17905680</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3189-86362bb50da52e1c9e7509d656212014766f05f1baceb9a8043c36221491aac73</originalsourceid><addsrcrecordid>eNpVkE9LAzEQxYMotlY_gSA56mHrJOn-iQdBilWh1IN6DtnsbBvZ3ZRkW-i3d5cWrad5zPDmzfwIuWYwZgz4PZukEKVCwJgDpGMAJk_I8Ld7eqQH5CKEbwAuM5mekwFLJcRJBkNSLXC98m6JjTU07EKLdSdKm3sXbKC3i4_Z3QPVtNItUl1s0QekHrVprWto62hwNVJX0naFdKkLV9nGbmqa64AFNa5pvQ4t1V1AGy7JWamrgFeHOiJfs-fP6Ws0f395mz7NIyNYJqMsEQnP8xgKHXNkRmIagyySOOGMQ_dUkpQQlyzXBnOpM5gI0zk4m0imtUnFiDzu9643eY2Fwf6KSq29rbXfKaet-j9p7Eot3VZxSDl08SMi9gtMhyF4LH-9DFQPX_VoVY9W9fBVD79z3RzH_nkOtMUPhT6AsQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Thomsen, Henrik S ; Marckmann, Peter ; Logager, Vibeke B</creator><creatorcontrib>Thomsen, Henrik S ; Marckmann, Peter ; Logager, Vibeke B</creatorcontrib><description>Until recently it was believed that extracellular gadolinium based contrast agents were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some gadolinium based contrast agents may trigger the development of nephrogenic systemic fibrosis, a generalised fibrotic disorder, in renal failure patients. Accordingly, the use of gadodiamide and gadopentate dimeglumine for renal failure patients was banned in Europe in spring 2007. The same two compounds should only be used cautiously in patients with moderate renal dysfunction. The current paper reviews the situation (July 2007) regarding gadolinium based contrast agent and the severe delayed reaction to some of these agents. The fear of nephrogenic systemic fibrosis should not lead to a denial of a well indicated enhanced magnetic resonance imaging examination.</description><identifier>ISSN: 1470-7330</identifier><identifier>ISSN: 1740-5025</identifier><identifier>EISSN: 1470-7330</identifier><identifier>DOI: 10.1102/1470-7330.2007.0019</identifier><identifier>PMID: 17905680</identifier><language>eng</language><publisher>England: e-Med</publisher><subject>Contrast Media - adverse effects ; Fibrosis - chemically induced ; Gadolinium - adverse effects ; Humans ; Kidney - pathology ; Kidney Diseases - chemically induced ; Time Factors</subject><ispartof>Cancer imaging, 2007-09, Vol.7 (1), p.130-137</ispartof><rights>2007 International Cancer Imaging Society 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3189-86362bb50da52e1c9e7509d656212014766f05f1baceb9a8043c36221491aac73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072086/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072086/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17905680$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thomsen, Henrik S</creatorcontrib><creatorcontrib>Marckmann, Peter</creatorcontrib><creatorcontrib>Logager, Vibeke B</creatorcontrib><title>Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents</title><title>Cancer imaging</title><addtitle>Cancer Imaging</addtitle><description>Until recently it was believed that extracellular gadolinium based contrast agents were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some gadolinium based contrast agents may trigger the development of nephrogenic systemic fibrosis, a generalised fibrotic disorder, in renal failure patients. Accordingly, the use of gadodiamide and gadopentate dimeglumine for renal failure patients was banned in Europe in spring 2007. The same two compounds should only be used cautiously in patients with moderate renal dysfunction. The current paper reviews the situation (July 2007) regarding gadolinium based contrast agent and the severe delayed reaction to some of these agents. The fear of nephrogenic systemic fibrosis should not lead to a denial of a well indicated enhanced magnetic resonance imaging examination.</description><subject>Contrast Media - adverse effects</subject><subject>Fibrosis - chemically induced</subject><subject>Gadolinium - adverse effects</subject><subject>Humans</subject><subject>Kidney - pathology</subject><subject>Kidney Diseases - chemically induced</subject><subject>Time Factors</subject><issn>1470-7330</issn><issn>1740-5025</issn><issn>1470-7330</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE9LAzEQxYMotlY_gSA56mHrJOn-iQdBilWh1IN6DtnsbBvZ3ZRkW-i3d5cWrad5zPDmzfwIuWYwZgz4PZukEKVCwJgDpGMAJk_I8Ld7eqQH5CKEbwAuM5mekwFLJcRJBkNSLXC98m6JjTU07EKLdSdKm3sXbKC3i4_Z3QPVtNItUl1s0QekHrVprWto62hwNVJX0naFdKkLV9nGbmqa64AFNa5pvQ4t1V1AGy7JWamrgFeHOiJfs-fP6Ws0f395mz7NIyNYJqMsEQnP8xgKHXNkRmIagyySOOGMQ_dUkpQQlyzXBnOpM5gI0zk4m0imtUnFiDzu9643eY2Fwf6KSq29rbXfKaet-j9p7Eot3VZxSDl08SMi9gtMhyF4LH-9DFQPX_VoVY9W9fBVD79z3RzH_nkOtMUPhT6AsQ</recordid><startdate>20070924</startdate><enddate>20070924</enddate><creator>Thomsen, Henrik S</creator><creator>Marckmann, Peter</creator><creator>Logager, Vibeke B</creator><general>e-Med</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20070924</creationdate><title>Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents</title><author>Thomsen, Henrik S ; Marckmann, Peter ; Logager, Vibeke B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3189-86362bb50da52e1c9e7509d656212014766f05f1baceb9a8043c36221491aac73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Contrast Media - adverse effects</topic><topic>Fibrosis - chemically induced</topic><topic>Gadolinium - adverse effects</topic><topic>Humans</topic><topic>Kidney - pathology</topic><topic>Kidney Diseases - chemically induced</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thomsen, Henrik S</creatorcontrib><creatorcontrib>Marckmann, Peter</creatorcontrib><creatorcontrib>Logager, Vibeke B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thomsen, Henrik S</au><au>Marckmann, Peter</au><au>Logager, Vibeke B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents</atitle><jtitle>Cancer imaging</jtitle><addtitle>Cancer Imaging</addtitle><date>2007-09-24</date><risdate>2007</risdate><volume>7</volume><issue>1</issue><spage>130</spage><epage>137</epage><pages>130-137</pages><issn>1470-7330</issn><issn>1740-5025</issn><eissn>1470-7330</eissn><abstract>Until recently it was believed that extracellular gadolinium based contrast agents were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some gadolinium based contrast agents may trigger the development of nephrogenic systemic fibrosis, a generalised fibrotic disorder, in renal failure patients. Accordingly, the use of gadodiamide and gadopentate dimeglumine for renal failure patients was banned in Europe in spring 2007. The same two compounds should only be used cautiously in patients with moderate renal dysfunction. The current paper reviews the situation (July 2007) regarding gadolinium based contrast agent and the severe delayed reaction to some of these agents. The fear of nephrogenic systemic fibrosis should not lead to a denial of a well indicated enhanced magnetic resonance imaging examination.</abstract><cop>England</cop><pub>e-Med</pub><pmid>17905680</pmid><doi>10.1102/1470-7330.2007.0019</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-7330 |
| ispartof | Cancer imaging, 2007-09, Vol.7 (1), p.130-137 |
| issn | 1470-7330 1740-5025 1470-7330 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2072086 |
| source | MEDLINE; PubMed Central Open Access; Springer Nature OA Free Journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Contrast Media - adverse effects Fibrosis - chemically induced Gadolinium - adverse effects Humans Kidney - pathology Kidney Diseases - chemically induced Time Factors |
| title | Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T04%3A53%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nephrogenic%20systemic%20fibrosis%20(NSF):%20a%20late%20adverse%20reaction%20to%20some%20of%20the%20gadolinium%20based%20contrast%20agents&rft.jtitle=Cancer%20imaging&rft.au=Thomsen,%20Henrik%20S&rft.date=2007-09-24&rft.volume=7&rft.issue=1&rft.spage=130&rft.epage=137&rft.pages=130-137&rft.issn=1470-7330&rft.eissn=1470-7330&rft_id=info:doi/10.1102/1470-7330.2007.0019&rft_dat=%3Cpubmed_cross%3E17905680%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17905680&rfr_iscdi=true |